PANCREATOLOGY

Can negative lymph node involvement and resection-free margins (ypT1-3N0R0) complete the disease-free survival benefit of a pathologic complete response (ypT0N0R0) in resected pancreatic cancer post neoadjuvant treatment?
Florou E, Zen Y, Srinivasan P and Prachalias A
Cost-effectiveness of biodegradable pancreatic stents in post-ERCP pancreatitis prophylaxis
Abbasi A, Anjum R, Tewatia P and Menon S
Biodegradable biliopancreatic stents (BDS) are commercially available alternatives to conventional stents. While these offer potential economic benefits-such as eliminating the need for follow-up imaging or endoscopic procedures to retrieve retained stents-they have not been evaluated in a cost-effectiveness model. We aimed to develop a health economic model comparing conventional pancreatic stents (PS) with BDS for the prophylaxis of post-ERCP pancreatitis (PEP).
PanSCOPE - Pancreatic cancer signature COllection for prognostic evaluation
Oketch DJA, Giulietti M and Piva F
Response to Letter to the Editor: "Bariatric surgery in pancreatic cancer: The double-edged sword of metabolic benefits and diagnostic challenges"
Dirweesh A and Amateau SK
Collective evidence for solid pseudopapillary neoplasm of the pancreas as a hormone-dependent tumor
Luo G
Pancreatic cancer risk in genetically determined chronic pancreatitis
Scherübl H
Methodological Considerations Regarding "Prognostic impact of serum triglycerides in acute pancreatitis"
Zhou W, Li L and Zhou X
The impact of opioid use in chronic pancreatitis from 2004-2024: A propensity-matched analysis of 183,214 individuals
Kilani Y, Madi MY, Obeid A, Heis F, Jiwon P, Gonzalez Mosquera DA, Nammour T, Drewes AM, Olesen SS and Farmer AD
Chronic pancreatitis is a progressive inflammatory disease causing exocrine and endocrine dysfunction, frequently leading to severe, recurrent pain necessitating treatment with opioid analgesics. The impact of opioid use on chronic pancreatitis outcomes is poorly understood.
FBXO22-mediated ubiquitination of KLF10 promoting pancreatic cancer proliferation and invasion
Liu X, He X, Hu Y, Xue Y, Jiang F and Wang X
Pancreatic cancer (PC) is a highly aggressive cancer with poor clinical outcomes. F-box only protein 22 (FBXO22), as an integral part of the SCF E3 ubiquitin ligase complex, has been associated with various cancers, but its role in PC remains underexplored.
Reevaluating rifaximin prophylaxis in severe acute pancreatitis: A call for methodological refinement and microbiome-centric endpoints
Aphale P, Shekhar H and Dokania S
Correlation between immune biomarkers and surrogate markers of severity of Acute Pancreatitis in an HIV endemic region
Madela F, Chiliza K, Mfeka X, Gopee K, Marin M, Kongstad M, Ostrowski S, Ghanizada M, Kløverpris H, Thomson S and Aldous C
Acute pancreatitis (AP) varies in severity, and traditional severity stratifications often fail to predict its early course. In people living with HIV (PLWH), chronic immune dysregulation leads to aberrant cytokine responses which influence biomarker performance. We hypothesize that in regions with high prevalence of HIV infection, HIV status will influence the immune biomarker performance in the prediction of severity of AP.
Pancreatic cancer: An urgent clinical challenges and opportunities for improved care
Mori Y, Takikawa T and Ohtsuka T
Clinical features and evolution of paraduodenal (groove) pancreatitis: A multicenter study
Rizzo GEM, Tacelli M, Crinò SF, Conti Bellocchi MC, De Pretis N, Amodio A, Binda C, Coluccio C, Anderloni A, Facciorusso A, Brunacci M, de Nucci G, Manes G, Fantin A, Stasi E, Salacone P, Crocella' L, Brancaccio ML, De Marchi F, Arcidiacono PG, Belfiori G, Falconi M, Carrara S, Antonini F, Fabbri C, Capurso G, Frulloni L, Barresi L and
The pathogenesis and natural history of paraduodenal (groove) pancreatitis (PP) remain unclear, and treatment includes medical therapy, interventional endoscopy, and surgery. This is a multicenter study to explore the burden of the disease, its clinical course, and response to treatment.
The "fat" fad in acute pancreatitis: Healing pancreas with fat
Singh N and Mahapatra SJ
Future of fluid therapy for acute pancreatitis
Windsor J, de-Madaria E and Buxbaum J
Prevalence, clinicopathological features, and prognosis of diabetes in pancreatic cancer: A single-center retrospective cohort study of 1620 patients
Li Y, Xiang S, Zhong W, Wang S, Zhang S, Zhang J, Du Y, Wang C and Che X
The interplay between pancreatic cancer (PC) and diabetes mellitus (DM) is complex, and may differ between new-onset DM (NODM) and long-standing DM (LSDM). We compared clinical features and prognosis across non-DM, NODM, and LSDM groups.
Serum autoantibody signatures enable non-invasive early detection of pancreatic cancer
Sun L, Liu Y, Yang Q, Zhu J, Li T, Jiang D, Lu Y, Liu L, Wang Y, Zhang X, Wang Z, Ma H, Shi J, Wang K, Wang P, Song C, Wang K and Ye H
Autoantibodies against tumor-associated antigens (TAAs) are promising biomarkers for early immunodiagnosis of cancers. This study was designed to screen and verify tumor-associated autoantibodies (TAAbs) in sera as diagnostic biomarkers for pancreatic cancer (PC).
ENDPAC model for defining a high-risk group for pancreatic cancer: Strengths, limitations and the way forward
Khan S and Chari ST
Complete pathological response in metastatic pancreatic adenocarcinoma following neoadjuvant therapy
Florou E, Zen Y, Dolly S, Srinivasan P and Prachalias A
Event timing inaccuracies in a retrospective study of low-dose aspirin and acute pancreatitis
Chen HD and Wang J
Plasma fatty acids, genetic risk, and incident pancreatic cancer: A prospective cohort study
Jiang W, Gu JM, Mao SQ, Lyu JQ, Shao XP, Liu ZY, Chen GC and Lu CD
Evidence regarding the association between circulating levels of fatty acids (FAs) and the risk of pancreatic cancer (PC) remains limited, and the effect modification by genetic risk status remains unclear.